依折麦布联合辛伐他汀在冠心病高脂血症患者中降脂疗效及安全性观察

目的评价依折麦布联合辛伐他汀对冠心病高脂血症患者的疗效及安全性。方法入选2011年6月至2013年8月在北京军区总医院干一科住院的冠心病高脂血症患者60例。随机分为对照组和治疗组,每组30例。检测患者治疗前后总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)水平,观察并记录不良反应。结果在对照组中,与治疗前比较,治疗后TC、TG和LDL-C均降低,差异具有统计学意义(P均0.05)。在治疗组中,与治疗前比较,治疗后TC、TG和LDL-C均降低,差异具有统计学意义(P均0.05)。与对照组治疗后比较,治疗组TC(4.10±1.24)mmol/L]、TG(1.64±0.75)mmol/L]和LDL-C(2.33±0.75)mmol/L]均降低,差异具有统计学意义(P均0.05)。药物降脂治疗后,对照组LDL-C的达标率为46.7%,治疗组为76.7%,差异有统计学意义(P0.05)。结论依折麦布联合辛伐他汀可达到强化降脂的效果,疗效优于单独应用辛伐他汀,且不良反应较少。

Lipid-lowering efficacy and safety of ezetimibe combining simvastatin in patients with coronary heart disease and hyperlipidemia

Objective To review the efficacy and safety of ezetimibe combining simvastatin in patients with coronary heart disease and hyperlipidemia. Methods The patients （n=60） were chosen from Jun. 2011 to Aug. 2013, and then randomly divided into control group and treatment group （each n=30）. The levels of total cholesterol （TC）, low-density lipoprotein-cholesterol （LDL-C）, high-density lipoprotein-cholesterol （HDL-C） and triglyceride （TG） were detected and adverse reactions were observed and recorded. Results The levels of TC, TG and LDL-C decreased in control group and treatment group （all P〈0.05） after treatment. Compared with control group after treatment, TC （4.10±1.24） mmol/L], TG （1.64±0.75） mmol/L] and LDL-C （2.33±0.75） mmol/L] decreased in treatment group （all P〈0.05）. After treatment, control rate of LDL-C was 46.7%in control group and 76.7%in treatment group （P〈0.05）. Conclusion Ezetimibe combining simvastatin can improve lipid-lowering efficacy, and the curative effect is superior to single simvastatin with less adverse reactions.